GILEAD SCIENCES, INC. — 13F Holdings & Portfolio
CIK 882095 · latest 13F-HR filed 2026-08-03
GILEAD SCIENCES, INC. manages $1.65B in 13F-reported U.S. long-equity assets across 5 reported positions as of its 2026-06-30 13F-HR filing. Its largest disclosed positions are RCUS (58.76%), LKFT (30.34%), ASMB (8.30%). Quarter over quarter (versus its 2026-03-31 filing) the fund opened 0 new positions, exited 1, added to 3, and trimmed 0.
AUM is the long-equity portion reported on Form 13F-HR. Excludes short positions, cash, foreign holdings, and non-13F assets. For informational purposes only — not investment advice.
FOSTER CITY, CA 94404
$1.65B
Long-equity book
5
Distinct positions
2026-06-30
Filed 2026-08-03
+0 / −1 / ↑3 / ↓0
vs 2026-03-31
| Name | Title / Status | Ownership | Type |
|---|
Top Adds (vs prior quarter)
- Arcus Biosciences Inc.$290.1M +42.7%
- Assembly Biosciences Inc.$11.7M +9.4%
- Xilio Therapeutics Inc.$761.0K +13.9%
Rows tagged Call or Put are options positions, not stock. Per SEC Form 13F-HR, Value shows the notional value of the underlying (shares covered × underlying price), not the option premium. Shares is the number of underlying shares covered (divide by 100 for contract count).
| # | Issuer | Symbol | CUSIP | Value | Weight | Shares | Type |
|---|---|---|---|---|---|---|---|
| 1 | Arcus Biosciences Inc. | RCUS | 03969F109 | $968.8M | 58.76% | 31,424,760 | SH |
| 2 | Lakefront Biotherapeutics | LKFT | 36315X101 | $500.2M | 30.34% | 16,707,477 | SH |
| 3 | Assembly Biosciences Inc. | ASMB | 045396207 | $136.8M | 8.30% | 4,977,089 | SH |
| 4 | Kyverna Therapeutics Inc. | KYTX | 501976104 | $36.8M | 2.23% | 4,126,119 | SH |
| 5 | Xilio Therapeutics Inc. | XLO | 98422T100 | $6.2M | 0.38% | 650,389 | SH |
| Period | Filed | AUM | Holdings | Accession |
|---|---|---|---|---|
| 2026-06-30 | 2026-08-03 | $1.65B | 5 | 0001123292-26-001034 |
| 2026-03-31 | 2026-05-08 | $2.12B | 6 | 0001123292-26-000642 |
| 2025-12-31 | 2026-02-12 | $1.94B | 6 | 0001123292-26-000164 |